WASHINGTON BIOTECHNOLOGY, INC.

 

In Vivo Services Update

                                             
In This Issue
Pancreatitis & Nephritis In Vivo Models
Quick Links
For information on all of our services, please visit
  
  
Rapid Turnaround  PK and MTD Studies in mice or rats; with or without quantitation.
  
- Start within 1 week of order 
- Dedicated Project Manager
- Detailed Report
  
WBI  in vivo  disease models include:
  

  
 

Prompt Start-up - Economical Pricing - Project Management - Full Reports

 

Pancreatitis and Nephritis

 In Vivo Models

Washington Biotechnology, Inc., a leader in In Vivo preclinical testing, introduces two new inflammatory disease models.

1. Pancreatitis Model (mouse)

Acute pancreatitis in humans is characterized by edema, cell necrosis and severe inflammation of the pancreas. The disease causes elevated blood and urine levels of the pancreatic digestive enzymes amylase and lipase.

Caerulein-Induced  Pancreatitis is a useful mouse model for screening therapeutic or prophylactic treatments.
 
We have validated and optimized this inflammation model for assessment of test compound efficacy. Our model is designed to rapidly assess therapeutic efficacy within a few hours by measurement of serum amylase activity. For compounds showing efficacy in this initial screen additional analysis is available through histopathology and myeloperoxidase (MPO) activity of pancreatic tissue.
 

1.1 Model:  Caerulein-induced acute pancreatitis in Balb/c mice

Study period:     

-        2 days

Readouts:

-        Plasma amylase activity (6 hours post injection of caerulein)

 

Optional:

-        Pancreatitic tissue:

o   Myeloperoxidase activity

o   Histopathology

 

Graph 1.1-1: Comparison of serum amylase activity after injection of Caerulein and PBS (as control)

 

  

 

2. Nephritis Models (rat)

Nephritis is an inflammation of one or both kidneys most often caused by autoimmune disease (lupus) but also triggered by other factors such as infection. Lupus nephritis is one of the most serious complications of the autoimmune disease, systemic lupus erythematosus (SLE), as a mjor predictor of a poor prognosis.

Disease development is associated with antibodies against single and double-stranded DNA, immune complex deposition, proteinuria and inflammatory cytokine and cell responses. Steroids and other immunosuppressive agents are used for treatments.

Animal models have been developed over the last few decades for investigation of immunopathology of this disease and to evaluate therapeutics.

 

2.1  PA-induced Nephritis Model (rat)

·        Nephritis induced by intravenous injection of puromycin aminonucleoside (PA)

·        SD rats

·        Study duration: 2 weeks

Basic Read-outs: Proteinuria response and blood urea nitrogen (BUN) assay

 

Optional:

·        kidney tissue histology (morphological changes of glomerulus and tabulointerstitium; severity of lesion)

·        Immunohistochemical staining on paraffin sections for the detection of infiltration monocytes /macrophages.

 

Graph 2.1-1 :  Proteinuria response after injection of PA versus PBS (as control)

 

 
 

Graph 2.1-2:  BUN assay (at day 13) after injection of PA versus PBS (as control)

 

 

 

 

 

2.2 Antibody-induced Nephritis Model (rat)

 

·        Nephritis induced by intravenous injection of anti-Thy1.1 monoclonal antibody (Ab)

·        Wistar rats

·        Study duration: 7 days

Basic Read-outs: Proteinuria response and blood urea nitrogen (BUN) assay

Optional:

·        kidney tissue histology (morphological changes of glomerulus and tabulointerstitium; severity of lesion)

·        Immunohistochemical staining on paraffin sections for the detection of infiltration monocytes /macrophages.

 

Graph 2.2-1:  Proteinuria response after injection of antibody versus PBS (as control)

Nephritis Ab-induced 
 

 

Graph 2.2-2:  BUN assay (at day 7) after injection of antibody versus PBS (as control)

 Nephritis - Ab induced BUN

 

 

References:

Foster, MH. "Relevance of systemic lupus erythematosus nephritis animal models to human disease".

Semin. Nephrol. 1999. 19(1): 12-24.

 

Salgado, A. and CH Diaz. "Review Article. Lupus Nephritis: An Overview of Recent Findings".

Autoimmune Diseases, 2012. 1-21.

 

  

 

For further information on these models, to request a consultation, or to receive a quotation, please contact us. Thank you.

 

 

 

 
 

WASHINGTON BIOTECHNOLOGY, INC. offers:

  • All services at our U.S. facility in Baltimore, Maryland
  • Competitive Pricing
  • Rapid start-up of studies
  • Fully detailed final reports
  • Standard or custom protocols 

Specialists in vaccine and compound testing with prophylactic or therapeutic protocols for:
  • Inflammation models
  • Arthritis models
  • Cancer - xenograft, orthotopic, syngeneic 
  • Bacterial infection models (antibiotic efficacy)  

Full in vitro support services:
  • Plasma, tissue, organ collections & preservations
  • Histology
  • Cytokine assays
  • Cell counts (total and differential)
  • Clinical chemistries

And for optimal dosing selection we offer:

  • MTD
  • PK
  • Toxicity - acute and chronic
  • Our staff recommendations for formulations, dosing routes and regimens

Please contact us  for expert recommendations on your intended vaccine or drug in vivo studies. Thank you.

Washington Biotechnology, Inc.
6200 Seaforth Street
Baltimore, MD 21224
USA
TEL: +1-410-633-9210
FAX: +1-410-633-9213
 Email (General Inquiries): wbio@washingtonbiotech.com